Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, Z. Estrov, MD, G. Garcia-Manero, MD, S. Verstovsek, MD, M. Browning, BSN, ADN, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 628.

https://doi.org/10.1182/blood.V110.11.628.628

Published: 2007

Journal Articles

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

William G. Wierda, MD, PhD, X. Wang, MS, S. OBrien, MD, S. Faderl, MD, A. Ferrajoli, MD, D. Thomas, MD, F. Ravandi, MD, J. Cortes, MD, F. Giles, MD, C. Koller, MD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MB BS

Blood (2005) 106 (11): 5018.

https://doi.org/10.1182/blood.V106.11.5018.5018

Published: 2005

Journal Articles

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, F. Giles, MD, J. Cortes, MD, D. Thomas, MD, F. Ravandi, MD, G. Garcia-Manero, MD, M. Andreeff, MD, S. Lerner, MS, H. Kantarjian, MD, M. Keating, MD

Blood (2005) 106 (11): 719.

https://doi.org/10.1182/blood.V106.11.719.719

Published: 2005

Journal Articles

Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy

M.J. Keating, S. O’Brien, S. Lerner, C. Koller, M. Beran, L.E. Robertson, E. J Freireich, E. Estey, H. Kantarjian

Blood (1998) 92 (4): 1165–1171.

https://doi.org/10.1182/blood.V92.4.1165

Published: 1998

Journal Articles

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

M Beran, H Kantarjian, S O'Brien, C Koller, M al-Bitar, S Arbuck, S Pierce, M Moore, JL Abbruzzese, M Andreeff, M Keating, E Estey

Blood (1996) 88 (7): 2473–2479.

https://doi.org/10.1182/blood.V88.7.2473.bloodjournal8872473

Published: 1996

Journal Articles

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

S O'Brien, H Kantarjian, M Keating, M Beran, C Koller, LE Robertson, J Hester, MB Rios, M Andreeff, M Talpaz

Blood (1995) 86 (9): 3322–3326.

https://doi.org/10.1182/blood.V86.9.3322.bloodjournal8693322

Published: 1995

Journal Articles

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy

S O'Brien, H Kantarjian, M Beran, LE Robertson, C Koller, S Lerner, MJ Keating

Blood (1995) 86 (4): 1298–1300.

https://doi.org/10.1182/blood.V86.4.1298.bloodjournal8641298

Published: 1995

Journal Articles

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]

S O'Brien, H Kantarjian, M Beran, T Smith, C Koller, E Estey, LE Robertson, S Lerner, M Keating

Blood (1993) 82 (6): 1695–1700.

https://doi.org/10.1182/blood.V82.6.1695.1695

Published: 1993

Journal Articles

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

MJ Keating, S O'Brien, H Kantarjian, W Plunkett, E Estey, C Koller, M Beran, EJ Freireich

Blood (1993) 81 (11): 2878–2884.

https://doi.org/10.1182/blood.V81.11.2878.2878

Published: 1993

Journal Articles

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

HM Kantarjian, M Beran, A Ellis, L Zwelling, S O'Brien, L Cazenave, C Koller, MB Rios, W Plunkett, MJ Keating

Blood (1993) 81 (5): 1146–1151.

https://doi.org/10.1182/blood.V81.5.1146.1146

Published: 1993

Journal Articles

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)

EH Estey, R Kurzrock, HM Kantarjian, SM O'Brien, KB McCredie, M Beran, C Koller, MJ Keating, C Hirsch-Ginsberg, YO Huh

Blood (1992) 79 (4): 882–887.

https://doi.org/10.1182/blood.V79.4.882.882

Published: 1992

Journal Articles

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

MJ Keating, H Kantarjian, M Talpaz, J Redman, C Koller, B Barlogie, W Velasquez, W Plunkett, EJ Freireich, KB McCredie

Blood (1989) 74 (1): 19–25.

https://doi.org/10.1182/blood.V74.1.19.19

Published: 1989

Journal Articles

Detection of leukemic clone maturation in vivo by premature chromosome condensation

WN Hittelman, P Agbor, I Petkovic, B Andersson, H Kantarjian, R Walters, C Koller, M Beran

Blood (1988) 72 (6): 1950–1960.

https://doi.org/10.1182/blood.V72.6.1950.1950

Published: 1988

NARROW

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

Detection of leukemic clone maturation in vivo by premature chromosome condensation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only